Bosh sahifaKYNB • NASDAQ
add
Kyntra Bio Inc
Yopilish kursi
7,10 $
Kunlik diapazon
7,01 $ - 7,40 $
Yillik diapazon
6,32 $ - 9,70 $
Bozor kapitalizatsiyasi
28,37 mln USD
Oʻrtacha hajm
39,56 ming
Narx/foyda
-
Dividend daromadliligi
-
Asosiy maydon
NASDAQ
Bozor yangiliklari
Moliyaviy axborot
Moliyaviy hisobot
Daromad
Sof foyda
| (USD) | dek, 2025info | Y/Y qiyosi |
|---|---|---|
Daromad | 1,28 mln | -59,27% |
Joriy xarajat | 7,25 mln | -13,13% |
Sof foyda | -14,22 mln | -179,08% |
Sof foyda marjasi | -1,11 ming | -294,14% |
Har bir ulushga tushum | -3,51 | -75,50% |
EBITDA | -13,51 mln | 49,92% |
Amaldagi soliq stavkasi | 0,00% | — |
Balans
Jami aktivlari
Jami passivlari
| (USD) | dek, 2025info | Y/Y qiyosi |
|---|---|---|
Naqd pul va qisqa investitsiyalar | 88,98 mln | 76,26% |
Jami aktivlari | 119,59 mln | -44,25% |
Jami passivlari | 115,12 mln | -71,09% |
Umumiy kapital | 4,48 mln | — |
Tarqatilgan aksiyalar | 4,05 mln | — |
Narxi/balansdagi bahosi | -0,96 | — |
Aktivlardan daromad | -26,34% | — |
Kapitaldan daromad | -110,83% | — |
Pul aylanmasi
Naqd pulning sof oʻzgarishi
| (USD) | dek, 2025info | Y/Y qiyosi |
|---|---|---|
Sof foyda | -14,22 mln | -179,08% |
Operatsiyalardan naqd pul | -18,33 mln | 39,84% |
Sarmoyadan naqd pul | -51,71 mln | -3 101,28% |
Moliyadan naqd pul | -14,00 ming | -380,00% |
Naqd pulning sof oʻzgarishi | -70,10 mln | -143,20% |
Boʻsh pul | -10,14 mln | 90,52% |
Haqida
Kyntra Bio, Inc. is a biopharmaceutical company headquartered in San Francisco, California. Once regarded as a promising developer of innovative therapies for anemia and fibrotic diseases, with a market capitalization of roughly $4 billion in 2018–19, the company's value collapsed following late-stage trial failures, regulatory setbacks, and a data manipulation scandal. By 2026, Kyntra was mainly reduced to a single early-stage oncology drug candidate.
On January 8, 2026, FibroGen changed its name to Kyntra Bio and ticker symbol to KYNB. Wikipedia
Tashkil etilgan
1-yan, 1993
Sayt
Xodimlar soni
34
